Brind.
  1. FDA granted Fast Track designation for NSCLC treatment, while MAIA entered a master clinical supply agreement with Roche, leading to international trial expansion.

MAIA Biotechnology began clinical trials, dosing the first patient in Taiwan and screening in Europe and Asia, with Regeneron providing Libtayo.

2 reports, 1 independent Updated Jul 10
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

MAIA Biotechnology began clinical trials, dosing the first patient in Taiwan and screening in Europe and Asia, with Regeneron providing Libtayo.

Who's involved

What this event is mainly about
Regeneron Pharmaceuticals

Keep exploring

Part of

FDA granted Fast Track designation for NSCLC treatment, while MAIA entered a master clinical supply agreement with Roche, leading to international trial expansion. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Clinical Trials ArenaMAIA Biotechnology doses first patient in expansion of Phase II lung cancer trial US-based MAIA Biotechnology has dosed the first subject in Taiwan in the expansion phase of its multicentre THIO-101
  • Unknown outlet